» Articles » PMID: 37006491

Urinary Proteome Profiles Associated with Cognitive Decline in Community Elderly Residents-A Pilot Study

Overview
Journal Front Neurol
Specialty Neurology
Date 2023 Apr 3
PMID 37006491
Authors
Affiliations
Soon will be listed here.
Abstract

Non-invasive and simple methods enabling easy identification of individuals at high risk of cognitive decline are needed as preventive measures against dementia. This pilot study aimed to explore protein biomarkers that can predict cognitive decline using urine, which can be collected non-invasively. Study subjects were selected from participants in a cohort study of middle-aged and older community-dwelling adults who underwent cognitive testing using the Mini-Mental State Examination and provided spot urine samples at two time points with an interval of approximately 5 years. Seven participants whose cognitive function declined 4 or more points from baseline (Group D) and 7 sex- and age-matched participants whose cognitive function remained within the normal range during the same period (Group M) were selected. Urinary proteomics using mass spectrometry was performed and discriminant models were created using orthogonal partial least squares-discriminant analysis (OPLS-DA). OPLS-DA yielded two models that significantly discriminated between the two groups at baseline and follow-up. Both models had ORM1, ORM2, and SERPINA3 in common. A further OPLS-DA model using baseline ORM1, ORM2, and SERPINA3 data showed similar predictive performance for data at follow-up as it did for baseline data (sensitivity: 0.85, specificity: 0.85), with the receiver operating characteristic curve analysis yielding an area under the curve of 0.878. This prospective study demonstrated the potential for using urine to identify biomarkers of cognitive decline.

Citing Articles

Recent progress in mass spectrometry-based urinary proteomics.

Joshi N, Garapati K, Ghose V, Kandasamy R, Pandey A Clin Proteomics. 2024; 21(1):14.

PMID: 38389064 PMC: 10885485. DOI: 10.1186/s12014-024-09462-z.


Proteomic and computational analyses followed by functional validation of protective effects of trigonelline against calcium oxalate-induced renal cell deteriorations.

Peerapen P, Boonmark W, Putpeerawit P, Sassanarakkit S, Thongboonkerd V Comput Struct Biotechnol J. 2023; 21:5851-5867.

PMID: 38074474 PMC: 10697849. DOI: 10.1016/j.csbj.2023.11.036.

References
1.
Katz R . Biomarkers and surrogate markers: an FDA perspective. NeuroRx. 2005; 1(2):189-95. PMC: 534924. DOI: 10.1602/neurorx.1.2.189. View

2.
Thomas S, Hao L, Ricke W, Li L . Biomarker discovery in mass spectrometry-based urinary proteomics. Proteomics Clin Appl. 2015; 10(4):358-70. PMC: 4888976. DOI: 10.1002/prca.201500102. View

3.
Soman A, Nair S . Unfolding the cascade of SERPINA3: Inflammation to cancer. Biochim Biophys Acta Rev Cancer. 2022; 1877(5):188760. DOI: 10.1016/j.bbcan.2022.188760. View

4.
Walker K . Inflammation and neurodegeneration: chronicity matters. Aging (Albany NY). 2018; 11(1):3-4. PMC: 6339781. DOI: 10.18632/aging.101704. View

5.
Zhan Z, Guan Y, Mew K, Zeng W, Peng M, Hu P . Urine α-fetoprotein and orosomucoid 1 as biomarkers of hepatitis B virus-associated hepatocellular carcinoma. Am J Physiol Gastrointest Liver Physiol. 2019; 318(2):G305-G312. DOI: 10.1152/ajpgi.00267.2019. View